Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines

Feleszko, Wojciech; Jalili, Ahmad; Olszewska, Dominika; Młynarczuk, Izabela; Grzela, Tomasz; Giermasz, Adam; Jakóbisiak, Marek

doi:10.3892/or.9.4.879

Cited by 11 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A synergic effect with other antineoplastic agents, including doxorrubicine and selective cyclooxygenase inhibitors, has been observed. 5,6 While our small sample size limited the statistical power, we found a similar trend for improvement in melanoma risk. Further evaluation of the anticancer effects for statin drugs with a larger sample is warranted.…”

supporting

confidence: 52%

Lipid‐lowering agents and risk of melanoma

Kirsner

Ramirez

Federman

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

supporting

confidence: 52%

Lipid‐lowering agents and risk of melanoma

Kirsner

Ramirez

Federman

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

“…[57][58][59] Other studies in cancer cells also showed enhanced apoptosis by cotreatments with statins and NSAIDs. 51,54,55,57 Our studies showed that atorvastatin decreased the level of membrane bound RhoA, presumably through inhibition of isoprenylation, and its combination with celecoxib significantly enhanced the effect. 56 This may suppress oncogenic activities of RhoA whose dysregulated functions are associated with cell cycle progression and increased invasiveness and metastasis of tumor cells.…”

Section: Mechanisms Of Actionsmentioning

confidence: 92%

“…51,[54][55][56] Recently, the in vivo efficacy of this type of combination has been investigated in animal models for prostate and intestinal cancers. In a xenograft tumor model, daily introperitoneal injections of high dose of atorvastatin (10 lg/g body weight) or celecoxib (10 lg/g body weight) showed little or no effect on the formation of androgen-independent prostate tumors that occurred after subcutaneous injection of PC-3 cells in male severe combined immunodeficient mice.…”

Section: Cancer Chemoprevention By the Combinations Of Statins And Nsmentioning

confidence: 99%

Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention

Xiao

Yang

2008

Intl Journal of Cancer

View full text Add to dashboard Cite

Statins and nonsteroidal antiinflammatory drugs (NSAIDs) are commonly prescribed for lowering cholesterol and antiinflammation, respectively. Recently, their potential roles as cancer chemopreventive agents have been subject to intensive studies. Human trials have not provided conclusive results on the protective effects of statins against different cancers, while more convincing results have been observed for cancer preventive effects of NSAIDs, especially on colorectal cancer. A promising strategy to enhance the cancer preventive efficacy of statins and NSAIDs is to use them in combination, which may produce synergy and lower the dose required for each agent. This strategy is of particular interest for potential use of low doses of statins and NSAIDs on a long-term basis for cancer chemoprevention; increased risks for gastrointestinal and cardiovascular side effects associated with the use of NSAIDs have been observed in colorectal cancer chemopreventive trials. This article reviews the evidence for the cancer preventive actions of statins and NSAIDs, as well as their possible synergistic action and the mechanisms involved. ' 2008 Wiley-Liss, Inc.Key words: statins; NSAIDs; cancer chemoprevention While the mortality from major chronic diseases, such as cardiovascular and cerebrovascular diseases, has decreased substantially during the past half century in the United States, the mortality from cancer has just begun to show a slight decrease. Cancer has become the number one killer of both men and women under age 85 years in the United States.1 A promising approach to controlling cancer is to prevent it before malignant events have occurred.2 Cancer chemoprevention refers to the use of natural or synthetic substances to inhibit, retard or reverse the carcinogenesis.3 A wealth of evidence from preclinical studies have convincingly demonstrated the cancer preventive efficacy of various agents in different animal models. However, the data from observational, case-control, cohort studies, and randomized trials in humans have overall demonstrated mixed results. Statins and nonsteroidal antiinflammatory drugs (NSAIDs) have been reported to be potential cancer chemopreventive agents. This review focuses on an attractive approach of chemoprevention using the combination of statins and NSAIDs. Statin and cancer chemopreventionStatins are small-molecule inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which are widely used as cholesterol-lowering drugs. Besides their use in the treatment of lipid disorders, statins have showed anticarcinogenic activities in many in vitro and in vivo preclinical studies, and attracted much attention in exploring their roles in cancer chemoprevention. Several observational human studies reported potential protective effects of statin use against overall risk of cancer, 4-6 whereas other studies did not 7,8 (Table I). In a case-control study in Quebec, Canada, statin use was found to be associated with a 28% reduction in the risk of developing cancer (RR 5 0.72, 95% ...

show abstract

“…has been shown in colon cancer cells (26,56,60,61). Furthermore, regular NSAID use, particularly aspirin, has been associated with a lower risk of prostate cancer in many observational studies (62)(63)(64)(65)(66)(67)(68)(69)(70)(71)(72).…”

Section: Discussionmentioning

confidence: 99%

Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort

Flick

Habel

Chan

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

136

115

View full text Add to dashboard Cite

Statins have known anticarcinogenic effects, however, evidence for long-term statin use as effective chemoprevention for prostate cancer is inconsistent. We examined the association between statin use and risk of prostate cancer among 69,047 eligible participants in the California Men's Health Study, a prospective cohort of Northern and Southern California Kaiser Permanente (KP) members, ages 45 to 69 years, initiated in 2002. Prostate cancer cases were identified by linkage to the KP California Cancer Registries. Statin exposure, estimated from automated KP outpatient pharmacy records (available since 1991 in Southern California and since 1994 in Northern California), was treated as time-varying and defined as the cumulative days dispensed of any statin from the first dispensing until a prostate cancer diagnosis, radical prostatectomy, termination of membership, or end of study (December 31, 2004). Cox proportional hazards models with age as the time scale were used to estimate rate ratios, while controlling for confounding variables. During follow-up, 888 prostate cancer cases, including 131 advanced cases, were identified. There was no association between ever statin use or <5 years use and prostate cancer. Conversely, ≥5 years use was associated with a 28% lower risk for prostate cancer compared with nonuse (adjusted rate ratio, 0.72; 95% confidence interval, 0.53-0.99). This association did not differ markedly for advanced disease. However, the association did seem to be restricted to those who regularly take nonsteroidal anti-inflammatory drugs. Our findings suggest that long-term statin use might be associated with a reduced risk of prostate cancer but perhaps only among regular nonsteroidal anti-inflammatory drug users. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2218–25)

show abstract

Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines

Cited by 11 publications

References 23 publications

Lipid‐lowering agents and risk of melanoma

Lipid‐lowering agents and risk of melanoma

Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention

Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort

Contact Info

Product

Resources

About